{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:58:05Z","timestamp":1791068285673,"version":"4.1.0"},"reference-count":37,"publisher":"American Psychiatric Association Publishing","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2003,8,1]]},"DOI":"10.1176\/appi.ajp.160.8.1413","type":"journal-article","created":{"date-parts":[[2003,8,4]],"date-time":"2003-08-04T17:35:14Z","timestamp":1060018514000},"page":"1413-1420","source":"Crossref","is-referenced-by-count":94,"title":["Is Regionally Selective D<sub>2<\/sub>\/D<sub>3<\/sub> Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [<sup>123<\/sup>I]Epidepride SPET Study of Amisulpride-Treated Patients"],"prefix":"10.1176","volume":"160","author":[{"given":"Rodrigo A.","family":"Bressan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell","family":"Erlandsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Ell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn S.","family":"Pilowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R1608BABGIHIB","doi-asserted-by":"crossref","unstructured":"Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G: Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33:227\u2013235","DOI":"10.1016\/0006-3223(93)90288-O"},{"key":"R1608BABDAADD","doi-asserted-by":"crossref","unstructured":"Kapur SJ, Zipursky R, Jones C, Remington G, Houle S: Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514\u2013520","DOI":"10.1176\/appi.ajp.157.4.514"},{"key":"R1608BABIHIDC","doi-asserted-by":"crossref","unstructured":"Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW: Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET study. Psychol Med 1993; 23:791\u2013797","DOI":"10.1017\/S0033291700025575"},{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW: Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340:199\u2013202","DOI":"10.1016\/0140-6736(92)90467-H"},{"key":"R1608BABCCJEG","doi-asserted-by":"crossref","unstructured":"Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538\u2013544","DOI":"10.1001\/archpsyc.1992.01820070032005"},{"key":"R1608BABFDGIA","doi-asserted-by":"crossref","unstructured":"Lidow MS, Goldman-Rakic PS: A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci USA 1994; 91:4353\u20134356","DOI":"10.1073\/pnas.91.10.4353"},{"key":"R1608BABDEHJJ","doi-asserted-by":"crossref","unstructured":"Meltzer HY: New insights into schizophrenia through atypical antipsychotic drugs. Neuropsychopharmacology 1988; 1:193\u2013196","DOI":"10.1016\/0893-133X(88)90015-2"},{"key":"R1608BABEHJAH","doi-asserted-by":"crossref","unstructured":"Kapur S, Seeman P: Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 2001; 158:360\u2013369","DOI":"10.1176\/appi.ajp.158.3.360"},{"key":"R1608BABDBFGI","unstructured":"Strange PG: Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001; 53:119\u2013133"},{"key":"R1608BABHCJGA","doi-asserted-by":"crossref","unstructured":"Bigliani V, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Stephenson C, Kerwin RW, Pilowsky LS: In vivo occupancy of striatal and temporal cortical D2\/D3 dopamine receptors by typical antipsychotic drugs: [123I]epidepride SPET study. Br J Psychiatry 1999; 175:231\u2013238","DOI":"10.1192\/bjp.175.3.231"},{"key":"R1608BABFEIJE","doi-asserted-by":"crossref","unstructured":"Xiberas X, Martinot JL, Mallet L, Artiges E, Loc\u2019h C, Maziere B, Paill\u00e8re-Martinot ML: Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001; 179:503\u2013508","DOI":"10.1192\/bjp.179.6.503"},{"key":"R1608BABGGJBD","doi-asserted-by":"crossref","unstructured":"Kessler RM, Ansari MS, Li R, Dawant B, Lee M, Meltzer HY: Occupancy of striatal and extrastriatal dopamine D2 receptors by atypical antipsychotic drugs. J Nucl Med 2002; 43:15P","DOI":"10.1016\/S0920-9964(03)81249-5"},{"key":"R1608BABEJECH","doi-asserted-by":"crossref","unstructured":"Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW: Limbic selectivity of clozapine. Lancet 1997; 350:490\u2013491","DOI":"10.1016\/S0140-6736(05)63079-6"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS: Striatal and temporal cortical D2\/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride SPET study. Psychopharmacology (Berl) 2000; 150:132\u2013140","DOI":"10.1007\/s002130000435"},{"key":"R1608BABGJAAA","doi-asserted-by":"crossref","unstructured":"Stephenson CM, Bigliani V, Jones HM, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Kerwin RW, Pilowsky LS: Striatal and extra-striatal D2\/D3 dopamine receptor occupancy by quetiapine in vivo: [123I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 2000; 177:408\u2013415","DOI":"10.1192\/bjp.177.5.408"},{"key":"R1608BABDECEJ","doi-asserted-by":"crossref","unstructured":"Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS: Optimizing limbic selective D2\/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 2003; 23:5\u201314","DOI":"10.1097\/00004714-200302000-00002"},{"key":"R1608BABBJGFH","unstructured":"Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B: Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280:83\u201397"},{"key":"R1608BABDFGEC","doi-asserted-by":"crossref","unstructured":"Trichard C, Paill\u00e8re-Martinot M-L, Attar-Levy D, Recassens C, Monnet F, Martinot J-L: Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 1998; 155:505\u2013508","DOI":"10.1176\/ajp.155.4.505"},{"key":"R1608BABBDJBD","doi-asserted-by":"crossref","unstructured":"Leucht S, Pitschel-Walz G, Engel RR, Kissling W: Amisulpride, an unusual \u201catypical\u201d antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159:180\u2013190","DOI":"10.1176\/appi.ajp.159.2.180"},{"key":"R1608BABEBFJD","doi-asserted-by":"crossref","unstructured":"Folstein MF, Folstein SE, McHugh PR: \u201cMini-Mental State\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189\u2013198","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"R1608BABDJBIH","doi-asserted-by":"crossref","unstructured":"Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799\u2013812","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"R1608BABCBDHD","doi-asserted-by":"crossref","unstructured":"Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261\u2013276","DOI":"10.1093\/schbul\/13.2.261"},{"key":"R1608BABJCFAC","doi-asserted-by":"crossref","unstructured":"Addington D, Addington J, Maticka-Tyndale E, Joyce J: Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992; 6:201\u2013208","DOI":"10.1016\/0920-9964(92)90003-N"},{"key":"R1608BABCEDDE","doi-asserted-by":"crossref","unstructured":"Endicott J, Spitzer RL, Fleiss JL, Cohen J: The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33:766\u2013771","DOI":"10.1001\/archpsyc.1976.01770060086012"},{"key":"R1608BABFFFGD","doi-asserted-by":"crossref","unstructured":"Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11\u201319","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"R1608BABCBGDB","doi-asserted-by":"crossref","unstructured":"Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672\u2013676","DOI":"10.1192\/bjp.154.5.672"},{"key":"R1608BABEFHEG","doi-asserted-by":"crossref","unstructured":"Lange K, Fessler JA: Globally convergent algorithms for maximum a posteriori transmission tomography. IEEE Trans Image Process 1995; 4:1430\u20131438","DOI":"10.1109\/83.465107"},{"key":"R1608BABBCBDB","doi-asserted-by":"crossref","unstructured":"Ogawa K, Harata Y, Ichihara T, Kubo A, Hashimoto S: A practical method for position-dependent Compton-scatter correction in single emission CT. IEEE Trans Med Imaging 2002; 10:408\u2013412","DOI":"10.1109\/42.97591"},{"key":"R1608BABHGFAG","doi-asserted-by":"crossref","unstructured":"Chang LT: A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978; 25:638\u2013643","DOI":"10.1109\/TNS.1978.4329385"},{"key":"R1608BABBECHB","doi-asserted-by":"crossref","unstructured":"Lammertsma AA, Hume SP: Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4:153\u2013158","DOI":"10.1006\/nimg.1996.0066"},{"key":"R1608BABFDEAF","doi-asserted-by":"crossref","unstructured":"Camps M, Cortes R, Gueye B, Probst A, Palacios JM: Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience 1989; 28:275\u2013290","DOI":"10.1016\/0306-4522(89)90179-6"},{"key":"R1608BABIGJAE","doi-asserted-by":"crossref","unstructured":"Martinot JL, Paill\u00e8re-Martinot ML, Poirier MF, Dao-Castellana MH, Loc\u2019h C, Maziere B: In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl) 1996; 124:154\u2013158","DOI":"10.1007\/BF02245616"},{"key":"R1608BABICGAH","doi-asserted-by":"crossref","unstructured":"Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc\u2019h C, Maziere B, Paill\u00e8re-Martinot ML: In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 2001; 21:207\u2013214","DOI":"10.1097\/00004714-200104000-00013"},{"key":"R1608BABIHJHI","doi-asserted-by":"crossref","unstructured":"Olsson H, Farde L: Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy\u2014a simulation study based on experimental data. Neuroimage 2001; 14:936\u2013945","DOI":"10.1006\/nimg.2001.0879"},{"key":"R1608BABBAFCI","doi-asserted-by":"crossref","unstructured":"Farde L, Wiesel FA, Halldin C, Sedvall G: Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45:71\u201376","DOI":"10.1001\/archpsyc.1988.01800250087012"},{"key":"R1608BABEBJFB","doi-asserted-by":"crossref","unstructured":"Tiihonen J, Kuoppamki M, Nagren K, Bergman J, Eronen E, Syvalahti E, Hietala J: Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology (Berl) 1996; 126:277\u2013280","DOI":"10.1007\/BF02247377"},{"key":"R1608BABBBIIA","doi-asserted-by":"crossref","unstructured":"Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47:27\u201338","DOI":"10.1177\/070674370204700106"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.160.8.1413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T20:13:31Z","timestamp":1722284011000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.160.8.1413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,1]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,8,1]]}},"alternative-id":["10.1176\/appi.ajp.160.8.1413"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.160.8.1413","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,1]]}}}